{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:49:18Z","timestamp":1782449358039,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1136\/ijgc-2024-005976","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:12:15Z","timestamp":1729599135000},"page":"1932-1939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-1223","authenticated-orcid":false,"given":"Lucy","family":"Haggstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-8263","authenticated-orcid":false,"given":"Yeh Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-3049","authenticated-orcid":false,"given":"Linn","family":"Woelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5452-4905","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen Nadine","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mar\u00eda","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":false,"given":"Michael L","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005976_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0015","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005976_bb0020","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005976_bb0025","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"JCO"},{"key":"10.1136\/ijgc-2024-005976_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0035","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ijgc-2023-004478","article-title":"Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency","volume":"33","author":"Monk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0040","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0045","author":"Coleman","year":"2022","journal-title":"O003\/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma"},{"key":"10.1136\/ijgc-2024-005976_bb0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0055","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1136\/ijgc-2024-005976_bb0060","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0065","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.21873\/anticanres.16202","article-title":"Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study","volume":"43","author":"Bourien","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2024-005976_bb0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejca.2022.12.023","article-title":"Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme","volume":"182","author":"Cueva","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/cer-2021-0135","article-title":"Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients","volume":"11","author":"Moya-Alarc\u00f3n","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1136\/ijgc-2024-005976_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2024.01.022","article-title":"Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group","volume":"184","author":"Musacchio","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0095","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ijgc-2023-004484","article-title":"Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Vilming","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-17-1621","article-title":"Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer","volume":"24","author":"Garsed","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005976_bb0105","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005976_bb0110","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2024-005976_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12916-024-03409-9","article-title":"Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer","volume":"22","author":"Li","year":"2024","journal-title":"BMC Med"},{"key":"10.1136\/ijgc-2024-005976_bb0120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0125","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005976_bb0130","first-page":"A15","author":"Mirza","year":"2023","journal-title":"#161 Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0135","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21873\/anticanres.15681","article-title":"Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study","volume":"42","author":"Gadducci","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2024-005976_bb0140","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ijgc-00009577-200601000-00061","article-title":"Routine follow-up after treatment for a gynecological cancer: a survey of practice","volume":"16","author":"Kew","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1136\/ijgc-2024-005976_bb0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005976_bb0155","first-page":"102629","article-title":"Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial","volume":"72","author":"Wu","year":"2024","journal-title":"eClin Med"},{"key":"10.1136\/ijgc-2024-005976_bb0160","author":"Government of Canada","year":"2023","journal-title":"Drug product database online query"},{"key":"10.1136\/ijgc-2024-005976_bb0165","author":"Australian Government: Department of Health and Aged Care","year":"2023","journal-title":"Therapeutic goods administration"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T01:07:51Z","timestamp":1764551271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24221940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1048891X24221940"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005976","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}